XTX Topco Ltd Grows Stock Holdings in Alector, Inc. (NASDAQ:ALEC)

XTX Topco Ltd grew its stake in shares of Alector, Inc. (NASDAQ:ALEC) by 62.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,069 shares of the company’s stock after acquiring an additional 11,978 shares during the period. XTX Topco Ltd’s holdings in Alector were worth $141,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ALEC. Vanguard Group Inc. lifted its holdings in Alector by 12.0% during the 1st quarter. Vanguard Group Inc. now owns 4,912,578 shares of the company’s stock worth $29,574,000 after purchasing an additional 526,037 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Alector by 16.2% in the first quarter. Jacobs Levy Equity Management Inc. now owns 922,799 shares of the company’s stock worth $5,555,000 after buying an additional 128,515 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Alector by 32.8% in the second quarter. Acadian Asset Management LLC now owns 590,662 shares of the company’s stock valued at $2,681,000 after acquiring an additional 146,015 shares during the period. Panagora Asset Management Inc. boosted its position in shares of Alector by 61.7% in the second quarter. Panagora Asset Management Inc. now owns 355,318 shares of the company’s stock valued at $1,613,000 after acquiring an additional 135,614 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in Alector by 21.5% during the second quarter. Bank of New York Mellon Corp now owns 279,938 shares of the company’s stock valued at $1,271,000 after acquiring an additional 49,625 shares in the last quarter. 85.83% of the stock is owned by institutional investors.

Alector Stock Performance

NASDAQ ALEC opened at $4.66 on Tuesday. Alector, Inc. has a 52-week low of $3.66 and a 52-week high of $8.90. The company has a fifty day moving average of $5.43 and a 200-day moving average of $5.31. The company has a market capitalization of $449.15 million, a P/E ratio of -3.38 and a beta of 0.68.

Alector (NASDAQ:ALEC) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. The firm had revenue of $15.08 million during the quarter, compared to analysts’ expectations of $16.04 million. Alector had a negative return on equity of 102.63% and a negative net margin of 290.66%. During the same period in the prior year, the business earned $0.02 EPS. As a group, analysts forecast that Alector, Inc. will post -1.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ALEC has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Alector in a research report on Thursday, June 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Alector in a research report on Tuesday, September 17th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $17.75.

Insider Buying and Selling at Alector

In other news, Director Paula Hammond sold 10,500 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $5.06, for a total value of $53,130.00. Following the completion of the sale, the director now directly owns 60,209 shares in the company, valued at approximately $304,657.54. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Arnon Rosenthal sold 26,499 shares of Alector stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total value of $129,315.12. Following the transaction, the chief executive officer now owns 1,948,746 shares in the company, valued at $9,509,880.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Paula Hammond sold 10,500 shares of Alector stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $5.06, for a total value of $53,130.00. Following the sale, the director now owns 60,209 shares in the company, valued at $304,657.54. The disclosure for this sale can be found here. Insiders have sold 58,222 shares of company stock worth $286,013 over the last ninety days. Insiders own 9.10% of the company’s stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.